Entera Bio

Entera Bio Long-term Debt

The Long-Term Debt of Entera Bio (ENTX) as of Oct 11, 2026 is 122,000.00 USD. In the previous year, Long-Term Debt was 3.89 M USD — a change of -96.87% (lower).

Long-term Debt

122,000.00USD

YoY

-96.87%

Last updated:

Long-Term Debt of Entera Bio is 2019 122,000.00 USD. Long-Term Debt of Entera Bio was 2018 3.89 M USD. It decreases by -96.87% lower compared to the previous year.

The Entera Bio Long-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Long-term Debt
Date
Long-term Debt
Jan 1, 2015
21.12 M USD
Jan 1, 2016
4.84 M USD
Jan 1, 2017
3.89 M USD
Jan 1, 2019
122,000.00 USD
The Entera Bio Long-term Debt history
YEARLong-term DebtYoY
122,000.00USD-96.87%
3.89 MUSD-19.48%
4.84 MUSD-77.10%
21.12 MUSD—
Access this data via the Eulerpool API
Get Free API Key

Entera Bio Stock analysis

What does Entera Bio do? Entera Bio Ltd is an emerging biotechnology company focused on developing oral medications to treat unmet medical needs. The company was founded in 2010 and is headquartered in Jerusalem, Israel. Its history began with the discovery of the "EnteraGam" molecule in the intestinal cells of breastfed infants, which helps them fight infections. This led to the development of EnteraGam for the treatment of various autoimmune diseases. The company's business model is based on developing oral formulations for existing drugs and discovering and developing new molecules. Its focus areas are osteoporosis, hypoparathyroidism, chronic kidney disease, and autoimmune diseases. Entera Bio is divided into three business divisions: the Oral Protein Delivery Platform, the Oral Parathyroid Hormone (PTH) Platform, and the Collagen-based Platform for Wound Healing. Its products include EB611, a candidate for hypoparathyroidism treatment, EB613 for osteoporosis treatment, and EB612 for chronic kidney disease. These products have potential to improve the lives of millions of patients worldwide. Entera Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Entera Bio stock

Long-Term Debt of Entera Bio is 122,000.00 USD in 2019.

Long-Term Debt of Entera Bio changed from 3.89 M USD to 122,000.00 USD, representing a -96.87% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Debt Entera Bio since 2006 – with annual values, charts, and detailed analysis.

Long-term debt represents obligations due after one year. It is a key component of a company's capital structure and leverage.

Long-Term Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Long-Term Debt's Entera Bio historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — Entera Bio

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Entera Bio